Apolipoprotein C-III (ApoC-III): what your result means.

A protein that slows triglyceride clearance; linked to cardiovascular risk. Apolipoprotein C-III (ApoC-III) is measured by blood test as part of the Cardiovascular panel in the HodieLabs Health Blueprint.

Why Apolipoprotein C-III (ApoC-III) matters

ApoC-III is a key regulator of triglyceride metabolism, elevated levels directly impair TG clearance. May explain elevated TG in patients who do not respond to standard lipid therapy.

Associated risks when out of range: Inhibits lipoprotein lipase, raising triglyceride-rich lipoproteins. Promotes hepatic VLDL secretion and impairs remnant clearance. Emerging therapeutic target (volanesorsen, olezarsen).

What the clinical evidence shows

The evidence base behind how the HodieLabs Evidence-Based Clinical Library interprets Apolipoprotein C-III (ApoC-III), from randomised trials, prospective cohorts and genetic (Mendelian randomisation) studies. Full citations in the reference list below.

• Exome Sequencing Project (NEJM 2014): people carrying loss-of-function APOC3 mutations had ~39% lower triglycerides and ~40% lower coronary heart disease risk, genetic proof that the ApoC-III pathway causally drives atherosclerosis.
• Copenhagen analysis (Jørgensen et al. NEJM 2014): APOC3 loss-of-function carriers in ~75,000 Danes showed the same protective pattern, independently replicating causality and making ApoC-III a prime therapeutic target now in clinical trials.

Evidence-based reference ranges

The HodieLabs Evidence-Based Clinical Library interprets Apolipoprotein C-III (ApoC-III) against published clinical authority standards, never arbitrary "optimal" ranges. Measured in mg/dL (lab dependent):

Band	Range (mg/dL (lab dependent))
Optimal	<10 mg/dL (lab dependent)
Borderline	10–15 mg/dL (lab dependent)
High	>15 mg/dL (lab dependent)

Clinical interpretation

• ApoC-III is a key regulator of triglyceride metabolism, elevated levels directly impair TG clearance.
• May explain elevated TG in patients who do not respond to standard lipid therapy.

What improves it: the evidence-based levers

• Lower TG drivers (carbs/alcohol/visceral fat)
• Consider specialist if persistently high

Recommended testing frequency: Annual, as part of a comprehensive panel. Single markers are always interpreted in context.

How Apolipoprotein C-III (ApoC-III) testing works at HodieLabs

Apolipoprotein C-III (ApoC-III) is measured in every Health Blueprint at our Melbourne Preventative Health & Longevity Clinic, interpreted by a doctor against the guideline-cited ranges above and tracked over time through your HodieLabs membership.

References

1. TG and HDL Working Group of the Exome Sequencing Project. Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med. 2014;371:22–31.
2. Jørgensen AB, et al. Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N Engl J Med. 2014;371:32–41.

This page is general information from the HodieLabs Evidence-Based Clinical Library, not medical advice. Speak with your GP about what testing and care is appropriate for you.